2022
Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis
Damsky W, Wang A, Kim DJ, Young BD, Singh K, Murphy MJ, Daccache J, Clark A, Ayasun R, Ryu C, McGeary MK, Odell ID, Fazzone-Chettiar R, Pucar D, Homer R, Gulati M, Miller EJ, Bosenberg M, Flavell RA, King B. Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis. Nature Communications 2022, 13: 3140. PMID: 35668129, PMCID: PMC9170782, DOI: 10.1038/s41467-022-30615-x.Peer-Reviewed Original ResearchConceptsType 1 immunityInternal organ involvementOrgan involvementT cell-derived IFNIdiopathic inflammatory disorderOpen-label trialMonths of treatmentType 1 cytokinesJanus kinase inhibitorImmunologic changesLongstanding sarcoidosisSarcoidosis activitySarcoidosis symptomsClinical improvementCutaneous sarcoidosisSecondary outcomesComplete responsePrimary outcomeTofacitinib treatmentActivity scoreCytokine mediatorsIL-12IL-15IL-6Inflammatory disorders
2017
Upper Airway Obstruction Requiring Emergent Tracheostomy Secondary to Laryngeal Sarcoidosis: A Case Report
Ryu C, Herzog EL, Pan H, Homer R, Gulati M. Upper Airway Obstruction Requiring Emergent Tracheostomy Secondary to Laryngeal Sarcoidosis: A Case Report. American Journal Of Case Reports 2017, 18: 157-159. PMID: 28190872, PMCID: PMC5319306, DOI: 10.12659/ajcr.902231.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsUpper airway obstructionRare extrapulmonary manifestationLaryngeal sarcoidosisLife-threatening complicationsAirway obstructionEmergent tracheostomyExtrapulmonary manifestationsCase reportComplete upper airway obstructionLow-dose prednisoneMonths of corticosteroidsStage 1 sarcoidosisAddition of methotrexateAfrican American femalesTapered dosageRespiratory failureSevere dyspneaInspiratory stridorSignificant morbidityPhysical examinationChronic careAryepiglottic foldsTimely diagnosisSarcoidosisPrednisone